Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. ORGALUTRAN (ganirélix)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ORGALUTRAN (ganirélix)

Medicine - Posted on Nov 07 2016 - Updated on Jun 12 2019
Active substance (DCI)
  • ganirélix
history (4)
  • 9/21/16

    ORGALUTRAN (ganirélix)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 6/6/12

    ORGALUTRAN (ganirélix)

    ORGALUTRAN (ganirélix)
    icône flèche
  • 2/14/07

    ORGALUTRAN (ganirélix)

    ORGALUTRAN (ganirélix)
    icône flèche
  • 4/18/01

    ORGALUTRAN 0,25 mg/0,5 ml, solution injectable en seringue pré-remplie (boîte de 1 et boîte de 5)

    ORGALUTRAN 0,25 mg/0,5 ml, solution injectable en seringue pré-remplie (boîte de 1 et boîte de 5)
    icône flèche
Technical information
ATC code
  • H01CC01
Manufacturer
MSD FRANCE
Presentation

ORGALUTRAN 0,25 mg/0,5 ml, solution injectable (code CIS : 62225235)

  • 1 seringue(s) préremplie(s) en verre de 0,5 ml - Code CIP : 3400935530189
  • 5 seringue(s) préremplie(s) en verre de 0,5 ml - Code CIP : 3400935530240
All our publications
    Drug therapy Endocrine system diseases Female genital diseases Sterility and assisted reproductive techniques

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
rMy0RnC8BgCVPkVJ